- Who we areWho we are
We are a biotechnology company committed to helping address serious infectious diseases globally through the discovery and development of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
- What we doWhat we do
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
COVID-19 UPDATESNovavax has demonstrated its ability to quickly develop viable vaccine candidates for emerging infectious diseases such as COVID-19.
- Blog
Novavax to Highlight RSV Program Data at Two Upcoming Meetings
Oral presentation details are as follows:
| IDWeek 2018 Meeting | ||
| Title: | Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Illness (LRTI) in Infants | |
| Presenter: | Louis F. Fries III, M.D., Senior Vice President and Chief Medical Officer, Novavax, Inc. | |
| Session: | 213. Late Breaker Oral Abstracts: Influenza and Vaccines | |
| Date and Time: | Saturday, October 6, 11:20 a.m. P.T. | |
| Location: | Moscone Convention Center S 152-154 | |
| 11th International Respiratory Syncytial Virus Symposium | ||
| Title: | Magnitude and Durability of Anti-F IgG and Palivizumab-Competitive Antibody (PCA) Responses One Year Following Immunization with RSV F Nanoparticle Vaccine Adjuvanted with Aluminum Phosphate, or a Novel Adjuvant | |
| Presenter: | Vivek Shinde, M.D., M.P.H., Executive Director, Clinical Development, Novavax, Inc. | |
| Session: | 5. Advancements in RSV Vaccines | |
| Date and Time: | Thursday, November 1, 4:45 p.m. – 6:15 p.m. E.T. | |
| Location: | Omni Grove Park Inn | |
| Title: | Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus Lower Respiratory Tract Illness (RSV LRTI) in Infants | |
| Presenter: | Louis F. Fries III, M.D., Senior Vice President and Chief Medical Officer, Novavax, Inc. | |
| Session: | 12. Maternal Immunity & Maternal Vaccination | |
| Date: | Saturday, November 3, 3:00 p.m. – 4:30 p.m. E.T. | |
| Location: | Omni Grove Park Inn | |
Poster presentations for the 11th International Respiratory Syncytial Virus Symposium will occur on
| Title: | Feasibility Evaluation of Blow Fill Seal Process and Compatibility with Aluminum Phosphate Adjuvanted Recombinant RSV F Nanoparticle Vaccine for Maternal Immunization | |
| Presenter: | Yen-Huei Lin, Ph.D., Senior Director, Formulation and Drug Product Development, Novavax, Inc. | |
| Title: | Binding Kinetics of RSVF Prefusogenic Vaccine to Palivizumab and Serum Polyclonal Antibody | |
| Presenter: | Hanxin Lu, Ph.D., Principal Scientist, Novavax, Inc. | |
| Title: | In-depth Analytical Characterization and Structural Modeling of Novavax RSV F Nanoparticle Vaccine | |
| Presenter: | Ernest Maynard, Ph.D., Principal Scientist, Analystical Development, Novavax, Inc. | |
| Title: | Antigenic Characterization Prefusogenic Nanoparticle Vaccine, Prefusion, and Postfusion F against a Broad Range of Neutralizing Monoclonal Antibodies and Epitope Responses in Cotton Rats | |
| Presenter: | Nita Patel, Director, Antibody Discovery, Vaccine Development Novavax, Inc. | |
| Title: | Respiratory Syncytial Virus (RSV) Prefusogenic F Nanoparticle Vaccine Compared to Prefusion and Postfusion RSV F: Physical and Antigenic Structure, Immunogenicity, and Protection | |
| Presenter: | Gale Smith, Ph.D., Vice President, Vaccine Development, Novavax, Inc. |
About
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts:
Investors
Senior Manager, Investor & Public Relations
[email protected]
240-268-2000
[email protected]
443-213-0506
Media
[email protected]
312-961-2502
